VectorBuilder's partner, Ucello, announced that its CD19-targeting umbilical cord blood-derived allogeneic CAR-T cell therapy ...

Qartemi is a 'living drug' that has been approved by the Central Drugs Standard Control Organisation (CDSCO) for blood cancer ...

London, UK-based Autolus said the CAR-T is the first to be approved ... Two rival CAR-Ts are currently approved by the FDA for relapsed or refractory B-cell precursor ALL, namely Novartis' Kymriah ...

Gilead’s CAR-T cancer therapy has been approved in the US for an aggressive form of blood cancer, indicating the company’s $12 billion acquisition on Kite Pharma could pay off. Priced at $ ...

On June 2, 2024, Caribou issued a press release announcing that it had “presented updated clinical data from the ongoing ANTLER Phase 1 trial that [purportedly] indicates a single dose of CB-010 . . .

SynKIR-310 is a chimeric antigen receptor (CAR) T-cell therapy that relies on DS191. Like commercially approved CAR T-cell therapies, SynKIR-310 is directed by DS191 to target a similar epitope of ...

The Economic Survey 2024-25 says on a global pedestal, India has successfully established itself as one of the top 20 medical ...

Bristol Myers on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Breyanzi for the treatment of adults with relapsed or refractory ...

The Independent Communications Authority of SA (Icasa) approved ... don’t intend to be building a whole product stack. We want to resell,” said Mendes. Mendes adds that Cell C’s brand ...

Do you remember the fall of your high school senior year—the college essays, endless applications, forms, decisions, the big ...

A cutting-edge gene therapy has been approved for NHS use for some patients with severe sickle cell disease. Casgevy, also known as exa-cel, was the first treatment to be licensed using gene ...